Review
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1981-1996
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1981
Table 1 Effect of mesenchymal stem cells-derived exosomes on gastrointestinal cancer
Tumor type
Exosomes source
Cell lines
Function
Mechanism
Ref.
Gastric cancerhUCMSCsHGC-27; MGC-803; SGC-7901Conferring tumor chemoresistance(1) Upregulating the expression of multi-drug resistance-associated genes and proteins; (2) Activating calcium/calmodulin-dependent protein kinases (CaMKs) and Raf/MEK/ERK pathway; and (3) Enhancing the functionality of P-gp/MDR[13]
hBMSCsAnimal modelPromoting tumor development(1) Activating ERK1/2 and p38 MAPK pathways; and (2) Enhancing the expression of VEGF[55]
hBMSCsSGC-7901No effectNA[55]
hUCMSCsHGC-27Promoting tumor development(1) Activating the Akt signal pathway; (2) Inducing the epithelial-mesenchymal transition (EMT); and (3) Enhancing the tumorigenicity and stemness[61]
hBMSCsSGC-7901Promoting tumor developmentSecreting miR-221 to activate Hedgehog signaling pathway[64]
GC-MSCsHGC-27Promoting tumor developmentIncreasing the expression of miR-214, miR-221, and miR-222[66]
mBMSCsMFCPromoting tumor developmentDelivering UBR2 to activate Wnt/β-catenin signaling pathway[69]
Liver cancerhBMSCsHepG-2Inhibiting tumor development(1) Blocking the cell cycle progression; and (2) Inducing tumor cells apoptosis[93]
AMSCsHepG-2Inhibiting tumor development and increasing tumor chemosensitivitySecreting miR-122 to improve chemosensitivity of HepG2 HCC cells and inhibiting tumor development[83]
AMSCsHuh-7; SMMC-7721Increasing tumor chemosensitivityDelivering miR-199a-3p to improve liver cancer cell line chemosensitivity[87]
mBMSCsAnimal modelInhibiting tumor development(1) Promoting tumor cells apoptosis; and (2) Inhibiting angiogenetic activity, metastasis, and invasiveness [96]
AMSCsAnimal modelInhibiting tumor developmentUpregulating local and systemic NK cells[95]
AMSCsHuh-7; SMMC-7721Increasing tumor chemosensitivityDelivering miR-199a-3p to tumor sites[87]
Pancreatic cancer hBMSCsBxPC-3; PANC-1Inhibiting tumor developmentSecreting miR-1231 to suppress tumor development[107]
hBMSCsPANC-1Inhibiting tumor development and promoting tumor cells apoptosisDownregulating the expression of a disintegrin and a metalloproteinase-9 (ADAM9)[108]
mBMSCsAsPC-1; PANC-1Inhibiting tumor development and promoting tumor cells apoptosisDelivering miR-124 to regulate the expression of EZH2[109]
mBMSCsCFPAC-1Inhibiting tumor developmentDelivering anticancer agents[47]
Normal fibroblast-like MSCsPANC-1Inhibiting tumor developmentDelivering short interfering RNA or short hairpin RNA to target oncogenic KRAS[105]
BMSCsMiaPaca-2Inhibiting tumor developmentLoading PTX and gemcitabine monophosphate (GEMP) to pancreatic cancer[100]
BMSCsTumor modelEnhancing tumor immunotherapyConstructing a dual delivery biosystem to achieve the combined therapy[106]
Colorectal cancer hBMSCsSW-480Promoting tumor developmentActivating ERK1/2, p38, and JNK pathways[55]
BMSCsCaco-2; SW-480; SW-620; LoVo; HT-29Inhibiting tumor development and promoting tumor cells apoptosisUpregulating the expression of miR-16-5p to downregulate integrin α2 (ITGA2)[124]
BMSCsDLD-1; HCT-116; SW-480Inhibiting tumor developmentSecreting miR-4461 to downregulate the expression of COPB2[125]
BMSCsSW-1116; Caco-2Inhibiting tumor development and promoting CSCs phenotypeSecreting miR-142-3p to decrease the expression of Numb. (1) Increasing the expression of Notch target genes; and (2) Secreting miR-142-3p to target CD133 and Lgr5[126][127]
hUCMSCsHT-29; DLD-1Inhibiting tumor development(1) Downregulating the expression of Integrin alpha6 (ITGA6); and (2) Inhibiting the activity of transforming growth factor-beta1 (TGF-β1) signaling pathway[128]
mBMSCsC-26; MCF-7Inhibiting tumor developmentLoading doxorubicin (DOX) to tumor cells[132]